These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

508 related articles for article (PubMed ID: 29080382)

  • 1. Factor XIII cotreatment with hemostatic agents in hemophilia A increases fibrin α-chain crosslinking.
    Beckman JD; Holle LA; Wolberg AS
    J Thromb Haemost; 2018 Jan; 16(1):131-141. PubMed ID: 29080382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma fibrin clots of pulmonary embolism patients present increased amounts of factor XIII and alpha2-antiplasmin at 3 months' anticoagulation since the acute phase.
    Zabczyk M; Natorska J; Bagoly Z; Sarkady F; Barath B; Katona E; Bryk A; Zettl K; Wisniewski JR; Undas A
    J Physiol Pharmacol; 2020 Aug; 71(4):. PubMed ID: 33214340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of recombinant factor VIIa (FVIIa) in fibrin structure in the absence of FVIII/FIX.
    He S; Blombäck M; Jacobsson Ekman G; Hedner U
    J Thromb Haemost; 2003 Jun; 1(6):1215-9. PubMed ID: 12871322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factor XIII combined with recombinant factor VIIa: a new means of treating severe hemophilia A.
    Rea CJ; Foley JH; Ingerslev J; Sørensen B
    J Thromb Haemost; 2011 Mar; 9(3):510-6. PubMed ID: 21155966
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Compaction of fibrin clots reveals the antifibrinolytic effect of factor XIII.
    Rijken DC; Abdul S; Malfliet JJ; Leebeek FW; Uitte de Willige S
    J Thromb Haemost; 2016 Jul; 14(7):1453-61. PubMed ID: 27148673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factor XIIIa-dependent retention of red blood cells in clots is mediated by fibrin α-chain crosslinking.
    Byrnes JR; Duval C; Wang Y; Hansen CE; Ahn B; Mooberry MJ; Clark MA; Johnsen JM; Lord ST; Lam WA; Meijers JC; Ni H; Ariëns RA; Wolberg AS
    Blood; 2015 Oct; 126(16):1940-8. PubMed ID: 26324704
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FXIII: mechanisms of action in the treatment of hemophilia A.
    Rea CJ; Foley JH; Okaisabor O; Sørensen B
    J Thromb Haemost; 2014 Feb; 12(2):159-68. PubMed ID: 24354581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factor XIII deficiency enhances thrombin generation due to impaired fibrin polymerization - An effect corrected by Factor XIII replacement.
    Pitkänen HH; Jouppila A; Lemponen M; Ilmakunnas M; Ahonen J; Lassila R
    Thromb Res; 2017 Jan; 149():56-61. PubMed ID: 27902939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Whole blood clot formation phenotypes in hemophilia A and rare coagulation disorders. Patterns of response to recombinant factor VIIa.
    Sørensen B; Ingerslev J
    J Thromb Haemost; 2004 Jan; 2(1):102-10. PubMed ID: 14717973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant factor VIIa analog NN1731 (V158D/E296V/M298Q-FVIIa) enhances fibrin formation, structure and stability in lipidated hemophilic plasma.
    Gray LD; Hussey MA; Larson BM; Machlus KR; Campbell RA; Koch G; Ezban M; Hedner U; Wolberg AS
    Thromb Res; 2011 Dec; 128(6):570-6. PubMed ID: 21561645
    [TBL] [Abstract][Full Text] [Related]  

  • 11. General haemostatic agents--fact or fiction?
    Hedner U
    Pathophysiol Haemost Thromb; 2002; 32 Suppl 1():33-6. PubMed ID: 12214145
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant factor VIIa (eptacog alfa): a review of its use in congenital hemophilia with inhibitors, acquired hemophilia, and other congenital bleeding disorders.
    Croom KF; McCormack PL
    BioDrugs; 2008; 22(2):121-36. PubMed ID: 18345709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concizumab improves clot formation in hemophilia A under flow.
    Jewell MP; Ashour Z; Baird CH; Manco Johnson M; Warren BB; Wufsus AR; Pallini C; Dockal M; Kjalke M; Neeves KB
    J Thromb Haemost; 2024 Sep; 22(9):2438-2448. PubMed ID: 38815755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel therapeutic approach combining human plasma-derived Factors VIIa and X for haemophiliacs with inhibitors: evidence of a higher thrombin generation rate in vitro and more sustained haemostatic activity in vivo than obtained with Factor VIIa alone.
    Tomokiyo K; Nakatomi Y; Araki T; Teshima K; Nakano H; Nakagaki T; Miyamoto S; Funatsu A; Iwanaga S
    Vox Sang; 2003 Nov; 85(4):290-9. PubMed ID: 14633255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potentiation of thrombin generation in hemophilia A plasma by coagulation factor VIII and characterization of antibody-specific inhibition.
    Doshi BS; Gangadharan B; Doering CB; Meeks SL
    PLoS One; 2012; 7(10):e48172. PubMed ID: 23144741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of factor XIII in ischemic stroke: a key molecule promoting thrombus stabilization and resistance to lysis.
    Marta-Enguita J; Navarro-Oviedo M; Machado FJDM; Bermejo R; Aymerich N; Herrera M; Zandio B; Pagola J; Juega J; Marta-Moreno J; Rodriguez JA; Páramo JA; Roncal C; Muñoz R; Orbe J
    J Thromb Haemost; 2024 Apr; 22(4):1080-1093. PubMed ID: 38160727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protransglutaminase (factor XIII) mediated crosslinking of fibrinogen and fibrin.
    Siebenlist KR; Meh DA; Mosesson MW
    Thromb Haemost; 2001 Nov; 86(5):1221-8. PubMed ID: 11816711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factor XIII in plasma, but not in platelets, mediates red blood cell retention in clots and venous thrombus size in mice.
    Kattula S; Byrnes JR; Martin SM; Holle LA; Cooley BC; Flick MJ; Wolberg AS
    Blood Adv; 2018 Jan; 2(1):25-35. PubMed ID: 29344582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced in vitro procoagulant and antifibrinolytic potential of superactive variants of recombinant factor VIIa in severe hemophilia A.
    Lisman T; de Groot PG; Lambert T; Røjkjaer R; Persson E
    J Thromb Haemost; 2003 Oct; 1(10):2175-8. PubMed ID: 14521601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thrombin generation and fibrinolysis in anti-factor IX treated blood and plasma spiked with factor VIII inhibitor bypassing activity or recombinant factor VIIa.
    Bolliger D; Szlam F; Molinaro RJ; Escobar MA; Levy JH; Tanaka KA
    Haemophilia; 2010 May; 16(3):510-7. PubMed ID: 20050927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.